10-K · March 10, 2026
Esperion reports accelerating commercial traction: FY25 total revenue grew 21% year-over-year to $403.1 million, driven by U.S. net product revenue of $159.6 million (up 38% Y/Y) and a strong Q4 2025 total quarter of…
Earnings analysis · 10-Q
ESPR earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Esperion Therapeutics, Inc. reported a revenue of $43.4 million in Q1 2026, up 24.3% from $34.9 million in Q1 2025, with significant growth registered in both product and collaboration revenues. Operating loss improved…
Read full summary
Esperion Therapeutics, Inc. reported a revenue of $43.4 million in Q1 2026, up 24.3% from $34.9 million in Q1 2025, with significant growth registered in both product and collaboration revenues. Operating loss improved to $6.6 million from a loss of $22.1 million in the prior year, signifying effective cost management despite ongoing challenges. However, the company continues to face liquidity pressures as cash used in operating activities reached $27.7 million during the quarter.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- Product Sales
- Segment
- Collaboration Revenue
What stood out
-
Strong Revenue Growth
Revenue increased by $8.5 million to $43.4 million in Q1 2026 from $34.9 million in Q1 2025.
-
Operating Loss Reduced
Improvement in operating loss to $6.6 million compared to $22.1 million in the same quarter last year.
-
Cash Reserves
As of March 31, 2026, cash and cash equivalents totaled $156.2 million, providing a solid liquidity base.
-
Cost Management Success
Research and development costs decreased by $3.6 million to $9.0 million in Q1 2026, aiding margin enhancements.
-
Collaboration Revenue Growth
Collaboration revenue rose to $36.7 million in Q1 2026, up from $30.1 million in Q1 2025, reflecting strength in partnerships.
-
Merger with Corstasis Completed
The $75 million acquisition of Corstasis was finalized on April 2, 2026, potentially advancing product offerings.
What to watch
-
Ongoing Operating Losses
Esperion has reported net losses continuously, posting a $25.2 million loss in Q1 2026 vs. $40.5 million in Q1 2025.
-
Material Weakness in Internal Controls
A material weakness in internal control was noted, affecting financial reporting accuracy.
-
High Interest Expenses
Interest expense increased to $19.8 million in Q1 2026, constraining cash flow and profitability.
Management's outlook
Management expressed that current cash resources and projected product revenues should sustain operations for the foreseeable future.
Earlier filings 4
10-Q · November 6, 2025
Esperion reported Q3 2025 revenue of $87.3M (up from $51.6M in Q3 2024) driven by higher collaboration revenue and product sales, but recorded a net loss of $31.3M (EPS -$0.16). Gross margin improved (revenues $87.3M…
10-Q · November 7, 2024
Esperion reported Q3 revenue of $51.632M, up from $33.969M in Q3 2023, driven by higher product sales ($31.106M vs $20.251M) and higher collaboration revenue ($20.526M vs $13.718M). Gross margin expanded to ~66.6% (COGS…
10-Q · May 7, 2024
Esperion reported a step-change quarter with total revenues of $137,735 (in thousands) in Q1 2024 versus $24,329 (in thousands) in Q1 2023, driven by a $112,979 (in thousands) collaboration milestone and higher product…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.